Your browser is no longer supported. Please, upgrade your browser.
Settings
GHDX Genomic Health, Inc. daily Stock Chart
GHDX [NASD]
Genomic Health, Inc.
Index- P/E- EPS (ttm)-0.13 Insider Own2.10% Shs Outstand34.62M Perf Week-1.82%
Market Cap1.14B Forward P/E97.08 EPS next Y0.34 Insider Trans-12.76% Shs Float33.85M Perf Month-1.61%
Income-4.40M PEG- EPS next Q0.07 Inst Own91.70% Short Float2.01% Perf Quarter15.03%
Sales336.00M P/S3.39 EPS this Y59.30% Inst Trans0.23% Short Ratio3.78 Perf Half Y9.63%
Book/sh5.04 P/B6.53 EPS next Y440.00% ROA-2.10% Target Price32.56 Perf Year15.47%
Cash/sh3.43 P/C9.58 EPS next 5Y5.50% ROE-2.60% 52W Range26.54 - 37.50 Perf YTD-3.77%
Dividend- P/FCF392.88 EPS past 5Y-29.50% ROI-10.80% 52W High-12.24% Beta0.50
Dividend %- Quick Ratio3.70 Sales past 5Y9.70% Gross Margin83.90% 52W Low24.00% ATR1.19
Employees846 Current Ratio3.70 Sales Q/Q1.80% Oper. Margin-2.10% RSI (14)42.70 Volatility3.63% 3.67%
OptionableYes Debt/Eq0.00 EPS Q/Q25.20% Profit Margin-1.30% Rel Volume2.19 Prev Close32.66
ShortableYes LT Debt/Eq0.00 EarningsFeb 13 Payout- Avg Volume180.36K Price32.91
Recom2.90 SMA20-1.92% SMA50-2.56% SMA2002.59% Volume395,878 Change0.77%
Dec-20-17Downgrade William Blair Outperform → Mkt Perform
Dec-13-17Downgrade JP Morgan Neutral → Underweight
May-03-17Downgrade Raymond James Outperform → Mkt Perform
Jan-18-17Initiated Deutsche Bank Hold $31
Feb-11-16Reiterated Canaccord Genuity Buy $44 → $38
Jan-11-16Downgrade Piper Jaffray Overweight → Neutral
Jan-07-16Reiterated Barclays Underweight $25 → $27
Jan-06-16Upgrade Canaccord Genuity Hold → Buy $26 → $44
Nov-23-15Upgrade UBS Neutral → Buy $29 → $38
Nov-04-15Upgrade Raymond James Mkt Perform → Outperform
Sep-02-15Initiated Barclays Underweight $25
Aug-28-15Upgrade Raymond James Underperform → Mkt Perform
Aug-05-15Reiterated Canaccord Genuity Hold $28 → $26
Mar-10-15Initiated UBS Neutral $34
Aug-11-14Reiterated Canaccord Genuity Hold $30 → $27
Aug-02-13Reiterated MLV & Co Hold $30 → $35
Feb-21-12Downgrade GARP Research Buy → Neutral
Feb-08-12Downgrade MLV & Co Buy → Hold $31.50 → $30
Dec-12-11Reiterated Ladenburg Thalmann Buy $26 → $32
Nov-02-11Upgrade Ladenburg Thalmann Neutral → Buy $26
Feb-06-18 09:30AM  Genomic Health (GHDX) Oncotype DX GPS Test Results Positive Zacks
Feb-05-18 08:00AM  Oncotype DX® Genomic Prostate Score Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care PR Newswire
Dec-28-17 08:30AM  Analysis: Positioning to Benefit within Genomic Health, Worthington Industries, Rambus, OMNOVA Solutions, CAI International, and Rudolph Technologies Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-21-17 08:00AM  Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-20-17 07:49AM  Innovation, Partnership Aid Genomic Health, Cost Woe Remains Zacks
Dec-18-17 08:38AM  Genomic Health at a 52-Week High: What's Driving the Stock? Zacks
Dec-15-17 07:19AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : December 15, 2017 Capital Cube +6.82%
Dec-14-17 01:56PM  Why Genomic Health, Inc. Skyrocketed Today Motley Fool +18.86%
Dec-12-17 09:17AM  Genomic Health (GHDX) Oncotype DX Score Test Data Positive Zacks
Dec-11-17 01:53PM  ETFs with exposure to Genomic Health, Inc. : December 11, 2017 Capital Cube
08:00AM  Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum PR Newswire
Dec-08-17 08:19AM  Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus Zacks
Dec-06-17 08:00AM  Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score Test for Potential Drug Development PR Newswire
Dec-01-17 10:38AM  ETFs with exposure to Genomic Health, Inc. : December 1, 2017 Capital Cube
Nov-30-17 09:38AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017 Capital Cube
08:00AM  Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging PR Newswire
Nov-29-17 11:50AM  Genomic Health-Cleveland Diagnostics Deal to Boost Test Suite Zacks
Nov-28-17 08:00AM  Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests PR Newswire
Nov-21-17 08:00AM  Genomic Health to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-17-17 03:00PM  Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes Zacks
Nov-16-17 10:39AM  Genomic Health, Inc. Turns a Profit (With an Asterisk) Motley Fool
01:02AM  Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE GlobeNewswire
Nov-12-17 04:41AM  Edited Transcript of GHDX earnings conference call or presentation 8-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 08:06AM  Genomic Health (GHDX) Swings to Earnings in Q3, Revenues Lag Zacks
Nov-08-17 04:43PM  Genomic Health reports 3Q loss Associated Press
04:05PM  Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress PR Newswire
Nov-01-17 08:00AM  Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017 PR Newswire
Oct-05-17 11:38AM  Genomic Health's Cost Pressure Mounts, Cancer Tests Strong Zacks
Sep-27-17 08:09AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 27, 2017 Capital Cube
Sep-26-17 10:52AM  ETFs with exposure to Genomic Health, Inc. : September 26, 2017 Capital Cube
06:56AM  Medicare reimbursement cuts slam stocks of lab services companies MarketWatch
Sep-25-17 04:25PM  Quest, LabCorp Are Big 'Losers' Under Medicare Overhaul: Analyst Investor's Business Daily
Sep-14-17 06:17PM  ETFs with exposure to Genomic Health, Inc. : September 14, 2017 Capital Cube
10:31AM  Genomic Health Ties up With Biocartis, Boosts Oncotype DX Zacks
Sep-13-17 11:52AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube
01:00AM  Genomic Health and Biocartis Announce Agreement to Develop an Idylla IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access PR Newswire
Sep-11-17 08:00AM  Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017 PR Newswire
Sep-05-17 09:47AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 5, 2017 Capital Cube
Aug-31-17 08:00AM  Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress PR Newswire
Aug-24-17 08:00AM  Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017 PR Newswire
Aug-13-17 09:10AM  Edited Transcript of GHDX earnings conference call or presentation 1-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:02PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : August 12, 2017 Capital Cube
Aug-03-17 10:00AM  Genomic Health, Inc.: Still Waiting for Reimbursement Motley Fool
Aug-02-17 11:08AM  Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2 Zacks -5.46%
08:06AM  Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings? Zacks
Aug-01-17 10:12PM  Genomic Health reports 2Q loss Associated Press
04:05PM  Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress PR Newswire
11:00AM  Investor Network: Genomic Health, Inc. to Host Earnings Call ACCESSWIRE
Jul-28-17 09:36AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : July 28, 2017 Capital Cube
Jul-20-17 08:00AM  Genomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017 PR Newswire
Jul-12-17 08:00AM  Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer PR Newswire
Jun-29-17 03:02PM  ETFs with exposure to Genomic Health, Inc. : June 29, 2017 Capital Cube
Jun-21-17 08:29AM  Genomic Health Cancer Tests Strong, Operating Expenses a Woe Zacks
Jun-14-17 09:47AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-13-17 03:41AM  Why Is Genomic Health (GHDX) Up 7.1% Since the Last Earnings Report? Zacks
Jun-02-17 08:00AM  Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types PR Newswire
Jun-01-17 12:06PM  Genomic Health to Unveil Oncotype DX Study Results at ASCO Zacks
May-31-17 08:45AM  Genomic Health (GHDX) Looks Good: Stock Adds 5.2% in Session Zacks
May-30-17 03:02PM  3 Things Investors Should Know About Genomic Health Stock Motley Fool +5.23%
08:00AM  Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types PR Newswire
May-25-17 08:00AM  Genomic Health to Present at Jefferies 2017 Healthcare Conference PR Newswire
May-17-17 09:01AM  Genomic Health Q1 Results Weak, Cancer Test Business Strong Zacks
May-16-17 09:41AM  Genomic Health's (GHDX) Oncotype DX GPS Test Data Positive Zacks
May-15-17 05:00PM  Genomic Health, Inc. Waits for Reimbursement Motley Fool
May-14-17 11:16PM  Edited Transcript of GHDX earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-13-17 07:00AM  Prospective Oncotype DX® Genomic Prostate Score Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer Patients PR Newswire
May-12-17 05:05PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : May 12, 2017 Capital Cube
12:48PM  Oncotype DX® Genomic Prostate Score (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease PR Newswire
May-11-17 10:15AM  Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates Zacks
08:58AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : May 11, 2017 Capital Cube
May-10-17 08:15PM  Edited Transcript of GHDX earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents -8.68%
08:00AM  Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference PR Newswire
May-09-17 05:40PM  Genomic Health reports 1Q loss Associated Press
04:05PM  Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress PR Newswire
10:15AM  Investor Network: Genomic Health, Inc. to Host Earnings Call Accesswire
May-08-17 08:15AM  Blog Coverage: Genomic Health Announces Favorable LCD on Medicare Coverage for Use of Oncotype DX Genomic Prostate Score Accesswire
May-04-17 04:05PM  Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score in Patients with Favorable Intermediate-risk Prostate Cancer PR Newswire
08:00AM  Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases PR Newswire
May-02-17 08:00AM  Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017 PR Newswire
Apr-26-17 09:30AM  Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings Zacks
Mar-30-17 09:47AM  Genomic Health's GPS Predicts Metastatic Prostate Cancer Zacks
09:47AM  Genomic Health's GPS Predicts Metastatic Prostate Cancer at Investopedia
06:45AM  New Research Shows Oncotype DX® Breast Cancer Test Helps Reduce Burden of Chemotherapy CNW Group
Mar-29-17 08:00AM  Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients PR Newswire
Mar-24-17 08:00AM  Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results PR Newswire
Mar-22-17 09:11AM  Genomic Health's Cancer Test Business Strong, Expenses High Zacks
07:20AM  Genomic Health (GHDX) Up 2.1% Since Earnings Report: Can It Continue? Zacks
Mar-21-17 01:04PM  GENOMIC HEALTH INC Financials
08:34AM  Genomic Health's Breast Recurrence Test Data Encouraging Zacks
Mar-20-17 08:00AM  Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy PR Newswire
Mar-15-17 04:30PM  GENOMIC HEALTH INC Files SEC form 10-K, Annual Report
Mar-07-17 01:23PM  The Best Bet in the Growing Genetic Testing Market: Genetic Health vs. Invitae Motley Fool
01:23PM  The Best Bet in the Growing Genetic Testing Market: Genetic Health vs. Invitae at Motley Fool
Feb-28-17 08:00AM  Genomic Health to Present at the Cowen and Company 37th Annual Health Care Conference PR Newswire
Feb-24-17 09:24AM  3 Most Wildly Overvalued Stocks in Healthcare at Motley Fool
Feb-22-17 02:17PM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017
Feb-21-17 07:11AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : February 21, 2017
Feb-16-17 11:05AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017 -8.42%
08:00AM  Four New Studies of Oncotype DX® Genomic Prostate Score (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection PR Newswire
Feb-15-17 07:34PM  Why Genomic Health Inc. Jumped Higher Today at Motley Fool +10.24%
Genomic Health, Inc. provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype SEQ Liquid Select test, a non-invasive liquid biopsy test, which uses next-generation sequencing to identify and select actionable genomic alterations to quantify the presence and burden of cancer, as well as helps to predict the sensitivity or resistance to specific drugs for patients with certain late-stage cancers, such as lung, breast, colon, melanoma, ovarian, or gastrointestinal cancers. Its development stage pipeline products include Oncotype TRACK products for non-invasive tumor monitoring. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreements with Epic Sciences, Inc. and BiocartisGroup NV; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Popovits Kimberly JPresident and CEOFeb 14Option Exercise17.1810,000171,80075,849Feb 15 04:02 PM
Popovits Kimberly JPresident and CEOFeb 14Sale32.9310,000329,33665,849Feb 15 04:02 PM
Popovits Kimberly JPresident and CEOJan 16Option Exercise17.1810,000171,80051,719Jan 18 09:30 PM
Popovits Kimberly JPresident and CEOJan 16Sale34.9910,000349,88541,919Jan 18 09:30 PM
Cole G BradleyCOOJan 09Option Exercise17.335,00086,65045,346Jan 10 09:17 PM
Cole G BradleyCOOJan 09Sale35.515,000177,56640,346Jan 10 09:17 PM
Vaughn James JChief Commercial OfficerJan 02Option Exercise17.332,16937,58930,481Jan 04 07:54 PM
Vaughn James JChief Commercial OfficerJan 02Sale34.093,004102,40627,477Jan 04 07:54 PM
Febbo Phillip G.Chief Medical OfficerDec 19Option Exercise27.005,000135,00023,134Dec 20 04:35 PM
Febbo Phillip G.Chief Medical OfficerDec 19Sale36.995,334197,29817,800Dec 20 04:35 PM
Leber LauraChief Communication OfficerDec 15Option Exercise17.339,000155,97024,754Dec 18 07:52 PM
Leber LauraChief Communication OfficerDec 15Sale35.009,000315,00015,754Dec 18 07:52 PM
Popovits Kimberly JPresident and CEODec 14Option Exercise17.2820,000345,53561,919Dec 18 07:51 PM
Leber LauraChief Communication OfficerDec 14Option Exercise21.5212,000258,24027,754Dec 18 07:52 PM
Leber LauraChief Communication OfficerDec 14Sale32.0012,000384,00015,754Dec 18 07:52 PM
Popovits Kimberly JPresident and CEODec 14Sale31.5020,000630,00041,919Dec 18 07:51 PM
Cole G BradleyCOODec 12Option Exercise17.335,00086,65044,935Dec 13 04:14 PM
Cole G BradleyCOODec 12Sale29.945,000149,70939,935Dec 13 04:14 PM
Cole G BradleyCOONov 07Option Exercise17.335,00086,65044,935Nov 09 04:59 PM
Cole G BradleyCOONov 07Sale31.475,000157,33039,935Nov 09 04:59 PM
Vaughn James JChief Commercial OfficerNov 02Option Exercise17.3392416,01328,999Nov 08 05:29 PM
Vaughn James JChief Commercial OfficerNov 02Sale32.511,37944,82727,620Nov 08 05:29 PM
Vaughn James JChief Commercial OfficerNov 01Option Exercise17.333,90767,70833,692Nov 08 05:29 PM
Vaughn James JChief Commercial OfficerNov 01Sale32.585,617183,00128,075Nov 08 05:29 PM
Cole G BradleyCOOOct 10Option Exercise17.335,00086,65044,935Oct 11 05:55 PM
Cole G BradleyCOOOct 10Sale31.935,000159,63739,935Oct 11 05:55 PM
Popovits Kimberly JPresident and CEOSep 14Option Exercise17.335,00086,65046,132Sep 18 04:02 PM
Popovits Kimberly JPresident and CEOSep 14Sale31.005,000154,98941,132Sep 18 04:02 PM
Cole G BradleyCOOSep 12Option Exercise17.335,00086,65044,935Sep 14 05:12 PM
Cole G BradleyCOOSep 12Sale31.865,000159,28839,935Sep 14 05:12 PM
Popovits Kimberly JPresident and CEOAug 14Option Exercise17.335,00086,65084,057Aug 16 08:02 PM
Popovits Kimberly JPresident and CEOAug 14Sale30.225,000151,11179,057Aug 16 08:02 PM
Cole G BradleyCOOAug 08Option Exercise17.335,00086,65044,935Aug 09 07:51 PM
Vaughn James JChief Commercial OfficerAug 08Option Exercise23.316,500151,51537,785Aug 09 07:52 PM
Vaughn James JChief Commercial OfficerAug 08Sale30.598,000244,72429,785Aug 09 07:52 PM
Cole G BradleyCOOAug 08Sale30.575,000152,84639,935Aug 09 07:51 PM
Febbo Phillip G.Chief Medical OfficerJul 19Sale33.573,174106,53817,800Jul 21 04:20 PM
Cole G BradleyCOOJul 11Option Exercise17.335,00086,65044,935Jul 13 05:23 PM
Cole G BradleyCOOJul 11Sale32.535,000162,66739,935Jul 13 05:23 PM
Popovits Kimberly JPresident and CEOJul 05Option Exercise17.331,46825,44080,525Jul 06 07:28 PM
Popovits Kimberly JPresident and CEOJul 05Sale32.671,46847,95279,057Jul 06 07:28 PM
Popovits Kimberly JPresident and CEOJul 03Option Exercise17.333,53261,21082,589Jul 06 07:28 PM
Popovits Kimberly JPresident and CEOJul 03Sale32.563,532114,98879,057Jul 06 07:28 PM
Shak StevenChief Scientific OfficerJun 23Option Exercise23.315,000116,550336,924Jun 27 06:11 PM
Shak StevenChief Scientific OfficerJun 23Sale33.275,000166,371331,924Jun 27 06:11 PM
Cole G BradleyCOOJun 13Option Exercise17.335,00086,65044,935Jun 15 04:40 PM
Cole G BradleyCOOJun 13Sale31.675,000158,34239,935Jun 15 04:40 PM
Popovits Kimberly JPresident and CEOJun 05Option Exercise17.335,00086,65084,057Jun 07 07:07 PM
Popovits Kimberly JPresident and CEOJun 05Sale32.325,000161,58279,057Jun 07 07:07 PM
BAKER BROS. ADVISORS LPDirectorMay 31Option Exercise18.1349,500897,43511,359,212Jun 01 05:19 PM
Shak StevenChief Scientific OfficerMay 23Option Exercise23.315,000116,550336,103May 25 04:39 PM
Shak StevenChief Scientific OfficerMay 23Sale29.405,000146,981331,103May 25 04:39 PM
Cohen Fred EDirectorMay 19Option Exercise14.378,250118,55374,145May 23 08:16 PM
Cohen Fred EDirectorMay 19Sale29.548,250243,74565,895May 23 08:16 PM
Cohen Fred EDirectorMay 18Option Exercise18.0516,500297,74382,395May 22 06:59 PM
Cohen Fred EDirectorMay 18Sale29.8816,500493,04065,895May 22 06:59 PM
Cohen Fred EDirectorMay 16Option Exercise18.138,250149,57374,145May 18 07:52 PM
Cohen Fred EDirectorMay 16Sale30.688,250253,10265,895May 18 07:52 PM
Popovits Kimberly JPresident and CEOMay 03Option Exercise17.335,00086,65083,236May 04 05:12 PM
Popovits Kimberly JPresident and CEOMay 03Sale31.775,000158,84978,236May 04 05:12 PM
Shak StevenChief Scientific OfficerApr 24Option Exercise23.315,000116,550336,103Apr 26 05:09 PM
Shak StevenChief Scientific OfficerApr 24Sale31.465,000157,323331,103Apr 26 05:09 PM
Popovits Kimberly JPresident and CEOApr 03Option Exercise20.805,000103,99283,236Apr 05 05:25 PM
Popovits Kimberly JPresident and CEOApr 03Sale31.305,000156,50778,236Apr 05 05:25 PM
Shak StevenChief Scientific OfficerMar 23Option Exercise23.315,000116,550336,103Mar 24 07:05 PM
Shak StevenChief Scientific OfficerMar 23Sale31.265,000156,295331,103Mar 24 07:05 PM
Leber LauraChief Communication OfficerMar 20Sale31.883,07297,94114,627Mar 22 04:03 PM
Cole G BradleyCOOMar 08Option Exercise23.315,610130,76945,338Mar 10 06:21 PM
Cole G BradleyCOOMar 08Sale31.555,710180,13439,528Mar 10 06:21 PM
Popovits Kimberly JPresident and CEOMar 06Option Exercise23.312906,76078,526Mar 07 08:34 PM
Popovits Kimberly JPresident and CEOMar 06Sale31.082909,01478,236Mar 07 08:34 PM
Popovits Kimberly JPresident and CEOMar 03Option Exercise23.314,710109,79082,946Mar 07 08:34 PM
Popovits Kimberly JPresident and CEOMar 03Sale31.094,710146,44078,236Mar 07 08:34 PM
Shak StevenChief Scientific OfficerFeb 23Option Exercise23.315,000116,550336,103Feb 27 09:56 PM
Shak StevenChief Scientific OfficerFeb 23Sale29.365,000146,815331,103Feb 27 09:56 PM